|
| Enzo Biochem, Inc. | | | | Enzo Biochem Reports Operating Results for Fiscal 2009 First Quarter
Enzo Biochem, Inc. a leading biotechnology company specializing in gene identification and genetic and immune regulation technologies for diagnostic and therapeutic applications, today announced operating results for the fiscal first quarter ended Total operating revenues for the period increased 8%, to $21.1 million, from $19.4 million in the corresponding year-ago period. Higher expenses resulting from the phase out of Enzo Clinical Labs legacy billing system and implementation during the quarter of a new billing and accounts receivable system affected Enzos contractual allowance and therefore revenues, and the provision for doubtful accounts. Also, a foreign exchange loss on an intercompany loan resulting from a strengthened dollar, along with sharply lower interest income primarily as a result of reduced money market rates, resulted in a first quarter net loss of $6.4 million, equal to (.17) per share, compared to a year ago loss of $1.2 million, or (.03) per share........
| | | | Advanced Cell Technology Inc. | | | | Advanced Cell Technology Licenses Non-Core Technology for $2.5 Million
Advanced Cell Technology, Inc. (OTC:ACTC) announced today that it has entered into a license with Ireland-based Transition Holdings, Inc, for certain of its non-core technology. Under the agreement, Transition agreed to acquire a license to the technology for $2.5 million, which includes the extinguishment of $1.5 million of debt and an additional funding commitment of $1 million. The intellectual property does not relate to any of the Companys advanced clinical programs. The Company expects to apply the proceeds it receives in the future towards its retinal pigment epithelium (RPE) cells program.“We are pleased to monetize this intellectual property in a way that raises non-dilutive capital for our shareholders, said William M. Caldwell IV, Chairman and CEO of Advanced Cell Technology, Inc. During a period when the capital markets remain highly challenging, particularly for small companies, we have been able to advance our clinical programs through funding from strategic partners like CHA Biotech Co, Ltd. and by the licensing of intellectual property unrelated to our core platform technologies....... | | | | interCLICK | | | | interCLICK Raises 4Q08 Revenue and Gross Margin Guidance interCLICK, Inc., one of the largest advertising networks in the U.S., provided today an update on its business outlook for its fourth quarter ending December 31, 2008. The Company now expects revenue for the fourth quarter to exceed $7 million, compared to its previous forecast for revenue to exceed $6.5 million. The Company also anticipates that 4Q08 gross margin will exceed 35%. Previously, interCLICK estimated that gross margin would exceed 31%. interCLICK is announcing today that it expects for the fourth quarter to report its first quarter of positive Adjusted EBITDA* since becoming a public company. A number of top-tier brands in the retail sector are employing interCLICK behavioral targeting platform to reach their target consumers during the holiday peak buying period, said Michael Mathews, interCLICK Chief Executive Officer. The effectiveness of interCLICKs behavioral targeting platform led to significant return on ad spend for these retail clients, prompting them to increase their spending -- a factor accounting for our higher revenue guidance"........ | | |
|
|